DTPa

Phase 3Biologic

GSK

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diphtheria-Tetanus-Acellular Pertussis VaccinesActive, not recruiting

Diphtheria-Tetanus-Acellular Pertussis VaccinesPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Diphtheria-Tetanus-Acellular Pertussis Vaccines

NCT07596199

Clinical

Trials by Indication[1]

Vaccination1 trial

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children

Completed· GSK logo

GSK·Phase 3·NCT01027845·360 enrolled

Radiotherapy1 trial

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

Terminated·—·Phase 1·NCT01034514·35 enrolled

Immunogenicity1 trial

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Completed· GSK logo

GSK·Phase 3·NCT00290342·458 enrolled

Diphtheria-Tetanus-acellular Pertussis Vaccines1 trial

A Phase 3, Non-Randomized, Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety and Reactogenicity of a Single Dose of Combined Reduced-Antigen-Content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine in Japanese Healthy Pregnant Women

Active, not recruiting· GSK logo

GSK·Phase 3·NCT07596199·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DTPa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DTPa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DTPa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK